Invasive fungal infection following venetoclax and posaconazole co-administration
- Author(s)
- Reynolds, G; Urbancic, KF; Fong, CY; Trubiano, JA;
- Details
- Publication Year 2023-09-20,Volume 203,Issue #4,Page 593-598
- Journal Title
- British Journal of Haematology
- Publication Type
- Research article
- Abstract
- The co-administration of venetoclax, a BCL-2 inhibitor, with a mould-active azole, such a posaconazole, has potential to both prevent invasive fungal infection (IFI) and reduce the required treatment dose, and cost, of venetoclax. Posaconazole drug-level monitoring is critical to ensuring adequate mould prophylaxis. A retrospective audit of 99 patients at a tertiary cancer centre, with myeloid malignancies co-prescribed venetoclax and posaconazole between January 2018 and April 2022, was undertaken to evaluate the adequacy of posaconazole prescribing and the rate of breakthrough IFI. Seventy-six patients (77%) had at least one posaconazole level measured in the study period, with 37% requiring a dose adjustment based on steady-state trough levels. Breakthrough IFI occurred in 4% of patients, typically within 1 month of commencing anti-mould prophylaxis. Close monitoring of posaconazole levels in venetoclax-treated patients, particularly in the early, outpatient setting, is critical.
- Publisher
- Wiley
- Keywords
- Bcl-2; Mds; antifungal; fungal infection; infection
- Department(s)
- Infectious Diseases
- PubMed ID
- 37731068
- Publisher's Version
- https://doi.org/10.1111/bjh.19116
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-11-21 05:54:29
Last Modified: 2024-07-16 04:22:31